Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innovent BiologicsIVBXF -0.02%77 Debt-to-Equity is 0.15 as of Dec. 2025, which is 21% below its 10-year median of 0.19. GuruFocus rates IVBXF with a GF Score™ of 77/100 and a GF Value™ of $13.33 (Fairly Valued). The stock has 3 warning signs investors should review. Among 965 Biotechnology companies, Innovent Biologics ranks better than 51.71% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Innovent Biologics's Debt-to-Equity or its related term are showing as below:
IVBXF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.36 Med: 0.19 Max: 0.3
Current: 0.15
During the past 10 years, the highest Debt-to-Equity Ratio of Innovent Biologics was 0.30. The lowest was -0.36. And the median was 0.19.
IVBXF's Debt-to-Equity is ranked better than 51.71% of 965
companies
in the Biotechnology industry
Industry Median: 0.15
vs IVBXF: 0.15
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Innovent Biologics Debt-to-Equity Related Terms
Innovent Biologics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Innovent Biologics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IVBXF vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Innovent Biologics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics (IVBXF) has a Debt-to-Equity of 0.15 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Innovent Biologics and its competitors. This is 21% below median its historical median of 0.19. According to the industry distribution chart, Innovent Biologics ranks #466 out of 965 companies in the Biotechnology industry, placing it in the top 48.3%.
Is Innovent Biologics' Debt-to-Equity too high?
Innovent Biologics' current Debt-to-Equity of 0.15 is 21% below median its 10-year median of 0.19. The Biotechnology industry median Debt-to-Equity is 0.15. Innovent Biologics' value of 0.15 is 0% at this industry median. Based on the distribution chart, Innovent Biologics ranks #466 out of 965 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Innovent Biologics has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovent Biologics ranks #466 out of 965 companies for Debt-to-Equity. This puts Innovent Biologics in the upper half of its industry. The industry median Debt-to-Equity is 0.15. Innovent Biologics' value of 0.15 is 0% at this benchmark. While the company's 10-year median is 0.19 vs. the industry median of 0.15, Innovent Biologics has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innovent Biologics's current Debt-to-Equity of 0.15 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Innovent Biologics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovent Biologics's current Debt-to-Equity is 0.15, which is 21% below median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (IVBXF) is currently considered Fairly Valued. The stock's GF Value™ is $13.33, compared to a current price of $12.37 — trading 7.2% below its estimated fair value. The current Debt-to-Equity is 0.15, which is 21% below median its 10-year median of 0.19 and 0% at the Biotechnology industry median of 0.15. Innovent Biologics' overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Innovent Biologics (IVBXF), the current Debt-to-Equity is 0.15 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovent Biologics (IVBXF) Overvalued in 2026?
Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued.
The current stock price of $12.37 is trading 7.2% below its estimated GF Value™ of $13.33.
GuruFocus considers Innovent Biologics to be Fairly Valued.
Key valuation signals for IVBXF:
Debt-to-Equity: 0.15 (21% below median its 10-year median of 0.19)
GF Value™: $13.33 vs. price of $12.37 (7.2% below fair value)
Industry Position: 0% at the Biotechnology median (#466 of 965)
No single metric tells the full story. See the IVBXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
77GF Score
Get the complete analysis for IVBXF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVBXF has been successfully added to your 
